Our Pipeline

At Servier Pharmaceuticals, our core business is focused in oncology where we believe that we have a unique opportunity to redefine how cancer is treated. We are committed to finding solutions that will address today's challenges. We aim to understand the needs of our patients at all points of their journey, while ensuring those who can benefit from our products have access to them. Advancing innovation for patients is at the heart of everything we do. Servier has significantly accelerated its investment in hard-to-treat cancers with more than 50% of research and development dedicated to deliver significant advances in areas of high unmet need that may truly move the needle for our patients. 

Servier’s pipeline includes many oncology assets at varying stages of clinical development

Hematological Malignancies

Molecule Area Primary Indication Partner Territory Phase

ONCASPAR®

(pegaspargase)

ALL
World
Registered
PRIMARY INDICATION
Acute Lymphoblastic Leukemia
PARTNER
PARTNER
World
PRIMARY INDICATION
Acute Lymphoblastic Leukemia
PARTNER
TERRITORY
World
Acute Lymphoblastic Leukemia
World

ONCASPAR is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with first line acute lymphoblastic leukemia (ALL), ALL and hypersensitivity to native forms of L-asparaginase.

ONCASPAR is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with first line acute lymphoblastic leukemia (ALL), ALL and hypersensitivity to native forms of L-asparaginase.

ASPARLAS

(calaspargase pegol-mknl)

ALL
World
Registered
PRIMARY INDICATION
Acute Lymphoblastic Leukemia
PARTNER
PARTNER
World
PRIMARY INDICATION
Acute Lymphoblastic Leukemia
PARTNER
TERRITORY
World
Acute Lymphoblastic Leukemia
World

ASPARLAS is indicated as a component of a multiagent chemotherapeutic regimen for the treatment of ALL in pediatric and young adult patients aged 1 month to 21 years.

ASPARLAS is indicated as a component of a multiagent chemotherapeutic regimen for the treatment of ALL in pediatric and young adult patients aged 1 month to 21 years.

TIBSOVO®

(ivosidenib tablets)

IDH1-AML
World except for China
Registered
PRIMARY INDICATION
IDH1-mutant Acute Myeloid Leukemia
PARTNER
Acquired by Servier from Agios Pharmaceuticals in 2021
PARTNER
World except for China
PRIMARY INDICATION
IDH1-mutant Acute Myeloid Leukemia
PARTNER
Acquired by Servier from Agios Pharmaceuticals in 2021
TERRITORY
World except for China
IDH1-mutant Acute Myeloid Leukemia
Acquired by Servier from Agios Pharmaceuticals in 2021
World except for China

TIBSOVO (ivosidenib tablets) is indicated in the U.S. for the treatment of acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA test in adult patients newly-diagnosed with AML who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy or adult patients with relapsed or refractory AML. 

TIBSOVO (ivosidenib tablets) is indicated in the U.S. for the treatment of acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA test in adult patients newly-diagnosed with AML who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy or adult patients with relapsed or refractory AML. 

Idhifa ®

(enasidenib)

IDH2-mutant R/R AML
Bristol Myers Squibb
United States
Registered
PRIMARY INDICATION
IDH2-mutant Relapsed or Refractory Acute Myeloid Leukemia
PARTNER
Servier acquired U.S. co-promotion and milestone rights for IDHIFA in 2021 from Agios Pharmaceuticals
PARTNER
United States
PRIMARY INDICATION
IDH2-mutant Relapsed or Refractory Acute Myeloid Leukemia
PARTNER
Servier acquired U.S. co-promotion and milestone rights for IDHIFA in 2021 from Agios Pharmaceuticals
TERRITORY
United States
IDH2-mutant Relapsed or Refractory Acute Myeloid Leukemia
Servier acquired U.S. co-promotion and milestone rights for IDHIFA in 2021 from Agios Pharmaceuticals
United States

IDHIFA (enasidenib) is indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.  

IDHIFA (enasidenib) is indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.  

PIXURVI®

(pixantrone)

NHL
World
Registered
PRIMARY INDICATION
Non-Hodgkin’s Lymphoma
PARTNER
PARTNER
World
PRIMARY INDICATION
Non-Hodgkin’s Lymphoma
PARTNER
TERRITORY
World
Non-Hodgkin’s Lymphoma
World

PIXURVI is indicated for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-Cell Lymphoma. PIXURVI is not registered in the United States.

PIXURVI is indicated for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-Cell Lymphoma. PIXURVI is not registered in the United States.

Anti-TIM-3

Lymphoma
Symphogen...
World
Phase 1
PRIMARY INDICATION
Lymphoma
PARTNER
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence.
PARTNER
World
PRIMARY INDICATION
Lymphoma
PARTNER
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence.
TERRITORY
World
Lymphoma
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence.
World

MCL1 Inhibitor

AML
Novartis
World except for North America and Japan
Phase 1
PRIMARY INDICATION
Acute Myeloid Leukemia*
PARTNER
Novartis
PARTNER
World except for North America and Japan
PRIMARY INDICATION
Acute Myeloid Leukemia*
PARTNER
Novartis
TERRITORY
World except for North America and Japan
Acute Myeloid Leukemia*
Novartis
World except for North America and Japan

*In combination with BCL-2 Inhibitor

*In combination with BCL-2 Inhibitor

BCL-2 Inhibitor

R/R AML + NHL + MM
Novartis
World except for North America and Japan
Phase 1
PRIMARY INDICATION
Relapsed/Refractory Acute Myeloid Leukemia + Non-Hodgkin’s Lymphoma + Multiple Myeloma
PARTNER
Novartis
PARTNER
World except for North America and Japan
PRIMARY INDICATION
Relapsed/Refractory Acute Myeloid Leukemia + Non-Hodgkin’s Lymphoma + Multiple Myeloma
PARTNER
Novartis
TERRITORY
World except for North America and Japan
Relapsed/Refractory Acute Myeloid Leukemia + Non-Hodgkin’s Lymphoma + Multiple Myeloma
Novartis
World except for North America and Japan

BCL- 2 Inhibitor

R/R AML
Novartis
World except for North America and Japan
Phase 1
PRIMARY INDICATION
Relapsed/Refractory Acute Myeloid Leukemia
PARTNER
Novartis
PARTNER
World except for North America and Japan
PRIMARY INDICATION
Relapsed/Refractory Acute Myeloid Leukemia
PARTNER
Novartis
TERRITORY
World except for North America and Japan
Relapsed/Refractory Acute Myeloid Leukemia
Novartis
World except for North America and Japan

BCL-2 Inhibitor

R/R NHL
Novartis
World except for North America and Japan
Phase 1
PRIMARY INDICATION
Relapsed/Refractory Non-Hodgkin’s Lymphoma
PARTNER
Novartis
PARTNER
World except for North America and Japan
PRIMARY INDICATION
Relapsed/Refractory Non-Hodgkin’s Lymphoma
PARTNER
Novartis
TERRITORY
World except for North America and Japan
Relapsed/Refractory Non-Hodgkin’s Lymphoma
Novartis
World except for North America and Japan

BCL-2 Inhibitor

R/R MM
Novartis
World except for North America and Japan
Phase 1
PRIMARY INDICATION
Relapsed/Refractory Multiple Myeloma
PARTNER
Novartis
PARTNER
World except for North America and Japan
PRIMARY INDICATION
Relapsed/Refractory Multiple Myeloma
PARTNER
Novartis
TERRITORY
World except for North America and Japan
Relapsed/Refractory Multiple Myeloma
Novartis
World except for North America and Japan

BCL-2 Inhibitor

R/R CLL
Novartis
Phase 1
PRIMARY INDICATION
R/R Chronic Lymphocytic Leukemia
PARTNER
Novartis
PARTNER
PRIMARY INDICATION
R/R Chronic Lymphocytic Leukemia
PARTNER
Novartis
TERRITORY
R/R Chronic Lymphocytic Leukemia
Novartis

Anti-CD19

R/R ALL Pediatric
Allogene Therapeutics
World except for the United States
Phase 1
PRIMARY INDICATION
Relapsed/Refractory Acute Lymphoblastic Leukemia Pediatric*
PARTNER
Allogene Therapeutics
PARTNER
World except for the United States
PRIMARY INDICATION
Relapsed/Refractory Acute Lymphoblastic Leukemia Pediatric*
PARTNER
Allogene Therapeutics
TERRITORY
World except for the United States
Relapsed/Refractory Acute Lymphoblastic Leukemia Pediatric*
Allogene Therapeutics
World except for the United States

​​​​​*Based on Cellectis TALEN® genome editing platform

​​​​​*Based on Cellectis TALEN® genome editing platform

Anti-CD19

R/R ALL Adult
Allogene Therapeutics
World except for the United States
Phase 1
PRIMARY INDICATION
Relapsed/Refractory Acute Lymphoblastic Leukemia Adult*
PARTNER
Allogene Therapeutics
PARTNER
World except for the United States
PRIMARY INDICATION
Relapsed/Refractory Acute Lymphoblastic Leukemia Adult*
PARTNER
Allogene Therapeutics
TERRITORY
World except for the United States
Relapsed/Refractory Acute Lymphoblastic Leukemia Adult*
Allogene Therapeutics
World except for the United States

​​​​​*Based on Cellectis TALEN® genome editing platform

​​​​​*Based on Cellectis TALEN® genome editing platform

Anti-CD19

R/R NHL
Allogene Therapeutics
World except for the United States
Phase 1
PRIMARY INDICATION
Relapsed/Refractory Non-Hodgkin’s Lymphoma*
PARTNER
Allogene Therapeutics
PARTNER
World except for the United States
PRIMARY INDICATION
Relapsed/Refractory Non-Hodgkin’s Lymphoma*
PARTNER
Allogene Therapeutics
TERRITORY
World except for the United States
Relapsed/Refractory Non-Hodgkin’s Lymphoma*
Allogene Therapeutics
World except for the United States

​​​​​*Based on Cellectis TALEN® genome editing platform

​​​​​*Based on Cellectis TALEN® genome editing platform

Anti-PD-1

Lymphoma
Symphogen...
World except for the United States
Phase 1
PRIMARY INDICATION
Lymphoma
PARTNER
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence.
PARTNER
World except for the United States
PRIMARY INDICATION
Lymphoma
PARTNER
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence.
TERRITORY
World except for the United States
Lymphoma
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence.
World except for the United States

Anti-LAG-3

Lymphoma
Symphogen...
World
Phase 1
PRIMARY INDICATION
Lymphoma
PARTNER
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence.
PARTNER
World
PRIMARY INDICATION
Lymphoma
PARTNER
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence.
TERRITORY
World
Lymphoma
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence.
World

Ivosidenib

IDH1-mutant R/R MDS
World except for China
Phase 1
PRIMARY INDICATION
Relapsed or Refractory Myelodysplastic Syndrome
PARTNER
PARTNER
World except for China
PRIMARY INDICATION
Relapsed or Refractory Myelodysplastic Syndrome
PARTNER
TERRITORY
World except for China
Relapsed or Refractory Myelodysplastic Syndrome
World except for China

Ivosidenib

IDH1-mutant IC-Ineligible Frontline AML
Phase 3
PRIMARY INDICATION
Intensive Chemotherapy-Ineligible Acute Myeloid Leukemia
PARTNER
PARTNER
PRIMARY INDICATION
Intensive Chemotherapy-Ineligible Acute Myeloid Leukemia
PARTNER
TERRITORY
Intensive Chemotherapy-Ineligible Acute Myeloid Leukemia

An ongoing phase 3 study, the AGILE trial is evaluating Ivosidenib + Azacitidine in adults with newly diagnosed AML and the IDH1 mutation who are not candidates for intensive treatment. 

An ongoing phase 3 study, the AGILE trial is evaluating Ivosidenib + Azacitidine in adults with newly diagnosed AML and the IDH1 mutation who are not candidates for intensive treatment. 

Ivosidenib

IDH1-mutant IC-Eligible Frontline AML
World except for China
Phase 3
PRIMARY INDICATION
Intensive Chemotherapy-Eligible Acute Myeloid Leukemia
PARTNER
PARTNER
World except for China
PRIMARY INDICATION
Intensive Chemotherapy-Eligible Acute Myeloid Leukemia
PARTNER
TERRITORY
World except for China
Intensive Chemotherapy-Eligible Acute Myeloid Leukemia
World except for China

HOVON 150 AML/AMLSG 29-18 is a phase 3, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in IC-eligible patients with newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with excess blasts-2, with an IDH1 or IDH2 mutation

HOVON 150 AML/AMLSG 29-18 is a phase 3, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in IC-eligible patients with newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with excess blasts-2, with an IDH1 or IDH2 mutation

Solid Tumors

Molecule Area Primary Indication Partner Territory Phase

Lonsurf®

(trifluridine/tipiracil)

mCRC Third Line
Taiho Pharmaceutical Co.
World except for the United States
Registered
PRIMARY INDICATION
Third line metastatic Colorectal Cancer
PARTNER
Taiho Pharmaceutical Co.
PARTNER
World except for the United States
PRIMARY INDICATION
Third line metastatic Colorectal Cancer
PARTNER
Taiho Pharmaceutical Co.
TERRITORY
World except for the United States
Third line metastatic Colorectal Cancer
Taiho Pharmaceutical Co.
World except for the United States

LONSURF (trifluridine and tipiracil) is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

LONSURF (trifluridine and tipiracil) is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

Lonsurf®

(trifluridine/tipiracil)

mCRC Second Line
Taiho Pharmaceutical Co.
World except for North America and Asia
Phase 1
PRIMARY INDICATION
Second line metastatic Colorectal Cancer*
PARTNER
Taiho Pharmaceutical Co.
PARTNER
World except for North America and Asia
PRIMARY INDICATION
Second line metastatic Colorectal Cancer*
PARTNER
Taiho Pharmaceutical Co.
TERRITORY
World except for North America and Asia
Second line metastatic Colorectal Cancer*
Taiho Pharmaceutical Co.
World except for North America and Asia

​​​​​*In combination with oxaliplatin and nivolumab or bevacizumab

​​​​​*In combination with oxaliplatin and nivolumab or bevacizumab

Lonsurf®

(trifluridine/tipiracil)

mCRC First Line
Taiho Pharmaceutical Co.
World except for North America and Asia
Phase 3
PRIMARY INDICATION
First line metastatic Colorectal Cancer*
PARTNER
Taiho Pharmaceutical Co.
PARTNER
World except for North America and Asia
PRIMARY INDICATION
First line metastatic Colorectal Cancer*
PARTNER
Taiho Pharmaceutical Co.
TERRITORY
World except for North America and Asia
First line metastatic Colorectal Cancer*
Taiho Pharmaceutical Co.
World except for North America and Asia

*In combination with bevacizumab

*In combination with bevacizumab

Lonsurf®

(trifluridine/tipiracil)

mGC Third Line
World except for North America and Asia
Registered
PRIMARY INDICATION
Third line metastatic Gastric Cancer
PARTNER
Taiho Pharmaceutical Co.
PARTNER
World except for North America and Asia
PRIMARY INDICATION
Third line metastatic Gastric Cancer
PARTNER
Taiho Pharmaceutical Co.
TERRITORY
World except for North America and Asia
Third line metastatic Gastric Cancer
Taiho Pharmaceutical Co.
World except for North America and Asia

LONSURF (trifluridine and tipiracil) is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

LONSURF (trifluridine and tipiracil) is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

Onivyde®

(Pegylated liposomal irinotecan)

mPAC post-gemcitabine
Ipsen
World except for the United States and Taiwan
Registered
PRIMARY INDICATION
Metastatic Pancreatic Adenocarcinoma*
PARTNER
Ipsen
PARTNER
World except for the United States and Taiwan
PRIMARY INDICATION
Metastatic Pancreatic Adenocarcinoma*
PARTNER
Ipsen
TERRITORY
World except for the United States and Taiwan
Metastatic Pancreatic Adenocarcinoma*
Ipsen
World except for the United States and Taiwan

ONIVYDE (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

*In combination with 5-FU/leucovorin

ONIVYDE (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

*In combination with 5-FU/leucovorin

Vorasidenib

IDH-mutant Low-Grade Glioma
World
Phase 3
PRIMARY INDICATION
IDH-mutant Low-Grade Glioma
PARTNER
PARTNER
World
PRIMARY INDICATION
IDH-mutant Low-Grade Glioma
PARTNER
TERRITORY
World
IDH-mutant Low-Grade Glioma
World

The INDIGO Study is a Phase 3 clinical trial evaluating the safety and effectiveness of vorasidenib in people with Grade 2 low-grade gliomas with an IDH mutation. 

The INDIGO Study is a Phase 3 clinical trial evaluating the safety and effectiveness of vorasidenib in people with Grade 2 low-grade gliomas with an IDH mutation. 

Anti-PD-1

Solid Tumors
Symphogen...
World
Phase 1
PRIMARY INDICATION
Solid Tumors: Programmed Cell Death Protein 1*
PARTNER
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. **
PARTNER
World
PRIMARY INDICATION
Solid Tumors: Programmed Cell Death Protein 1*
PARTNER
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. **
TERRITORY
World
Solid Tumors: Programmed Cell Death Protein 1*
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. **
World

*Monotherapy and in combination with Anti-LAG-3 or Anti-TIM-3

**License option not yet exercised

*Monotherapy and in combination with Anti-LAG-3 or Anti-TIM-3

**License option not yet exercised

Anti-LAG-3

Solid Tumors
Symphogen...
World
Phase 1
PRIMARY INDICATION
Solid Tumors- Lymphocyte-Activation Gene 3
PARTNER
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. *
PARTNER
World
PRIMARY INDICATION
Solid Tumors- Lymphocyte-Activation Gene 3
PARTNER
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. *
TERRITORY
World
Solid Tumors- Lymphocyte-Activation Gene 3
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. *
World

*License option not yet exercised

*License option not yet exercised

Anti-TIM-3

Solid Tumors
Symphogen...
World
Phase 1
PRIMARY INDICATION
Solid Tumors- T-cell Immunoglobulin and Mucin Domain Protein 3
PARTNER
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. *
PARTNER
World
PRIMARY INDICATION
Solid Tumors- T-cell Immunoglobulin and Mucin Domain Protein 3
PARTNER
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. *
TERRITORY
World
Solid Tumors- T-cell Immunoglobulin and Mucin Domain Protein 3
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. *
World

​​​​​​*License option not yet exercised

​​​​​​*License option not yet exercised

Ivosidenib

Previously treated IDH1-mutant CCA
World except for China
Phase 1
PRIMARY INDICATION
Previously treated IDH1-mutant Cholangiocarcinoma
PARTNER
PARTNER
World except for China
PRIMARY INDICATION
Previously treated IDH1-mutant Cholangiocarcinoma
PARTNER
TERRITORY
World except for China
Previously treated IDH1-mutant Cholangiocarcinoma
World except for China

Ivosidenib was investigated in the ClarIDHy study, a global, randomized Phase 3 trial in previously treated IDH1 mutant cholangiocarcinoma patients who have documented disease progression following one or two systemic therapies in the advanced setting. 

Ivosidenib was investigated in the ClarIDHy study, a global, randomized Phase 3 trial in previously treated IDH1 mutant cholangiocarcinoma patients who have documented disease progression following one or two systemic therapies in the advanced setting. 

AG-270

MTAP-Deleted Pancreatic Cancer
World
Phase 1
PRIMARY INDICATION
Methylthioadenosine phosphorylase -deleted pancreatic cancer
PARTNER
PARTNER
World
PRIMARY INDICATION
Methylthioadenosine phosphorylase -deleted pancreatic cancer
PARTNER
TERRITORY
World
Methylthioadenosine phosphorylase -deleted pancreatic cancer
World

AG-270

MTAP-Deleted NSCLC
Phase 1
PRIMARY INDICATION
Methylthioadenosine phosphorylase -deleted non-small cell lung cancer
PARTNER
PARTNER
PRIMARY INDICATION
Methylthioadenosine phosphorylase -deleted non-small cell lung cancer
PARTNER
TERRITORY
Methylthioadenosine phosphorylase -deleted non-small cell lung cancer

More from Servier

Research & Development

We invest in innovative research and development through our own development or partnerships to best address the unmet needs of patients.

Learn More

Clinical Trials

We strive to have consistent and concise transparency throughout all our clinical trials and research and development for the benefit of our patients.

Learn More

About Us

Servier Pharmaceuticals is a privately held pharmaceutical company focused on oncology. Everything we do is to bring the promise of tomorrow to the patients we serve.

Learn More